The startup develops human microbiota utilizing differentiated separation technology for anaerobic intestinal microbe strains, targeting the prevention of diverse diseases and enhancing cancer immunotherapy. Their approach enables physicians to perform multi-omics analysis, facilitating clinical research and drug discovery in metabolic and brain diseases.
Funding
Funding not disclosed
Founders
Product
Problem
The vast majority of gut microbiota (99.9%) are strict anaerobes, which are difficult to culture and study, yet they play a crucial role in human health, including disease prevention and treatment. Current methods lack efficient technologies for isolating, culturing, and analyzing these microbes to develop effective therapies.
Solution
HealthBiome is a microbiome-based drug discovery company focused on developing novel therapeutics based on strict anaerobic gut microbiota. The company leverages its proprietary technology for isolating and mass-culturing these fastidious organisms, combined with multi-omics analysis and non-clinical animal studies, to identify and develop effective treatments for a range of diseases. HealthBiome's research and development efforts are centered on identifying unique microbial strains and bioactive compounds with therapeutic potential in areas such as cancer, dementia, metabolic disorders, and inflammatory bowel disease. The company's approach involves isolating novel strains from the human gut microbiome, optimizing their production, and conducting preclinical studies to validate their efficacy and safety.
Target Audience
HealthBiome's primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions interested in developing novel microbiome-based therapeutics for various diseases.
Features
- Proprietary technology for isolating and mass-culturing strict anaerobic gut microbiota
- Multi-omics analysis platform for characterizing microbial strains and identifying bioactive compounds
- Preclinical animal models for evaluating the efficacy and safety of microbiome-based therapeutics
- Pipeline of drug candidates targeting cancer, dementia, metabolic disorders, and inflammatory bowel disease
- Focus on identifying and developing novel microbial strains with unique therapeutic properties
- Expertise in optimizing the production of strict anaerobic bacteria for therapeutic applications
- Patented and patent-pending technologies for microbiome-based drug discovery